Ultragenyx Ebit vs Total Operating Expenses Analysis
RARE Stock | USD 46.02 0.38 0.82% |
Ultragenyx financial indicator trend analysis is much more than just breaking down Ultragenyx prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Ultragenyx is a good investment. Please check the relationship between Ultragenyx Ebit and its Total Operating Expenses accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Ultragenyx. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Ultragenyx Stock refer to our How to Trade Ultragenyx Stock guide.
Ebit vs Total Operating Expenses
Ebit vs Total Operating Expenses Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Ultragenyx Ebit account and Total Operating Expenses. At this time, the significance of the direction appears to have pay attention.
The correlation between Ultragenyx's Ebit and Total Operating Expenses is -0.88. Overlapping area represents the amount of variation of Ebit that can explain the historical movement of Total Operating Expenses in the same time period over historical financial statements of Ultragenyx, assuming nothing else is changed. The correlation between historical values of Ultragenyx's Ebit and Total Operating Expenses is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Ebit of Ultragenyx are associated (or correlated) with its Total Operating Expenses. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Operating Expenses has no effect on the direction of Ebit i.e., Ultragenyx's Ebit and Total Operating Expenses go up and down completely randomly.
Correlation Coefficient | -0.88 |
Relationship Direction | Negative |
Relationship Strength | Significant |
Ebit
Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most indicators from Ultragenyx's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Ultragenyx current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Ultragenyx. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Ultragenyx Stock refer to our How to Trade Ultragenyx Stock guide.The current year's Selling General Administrative is expected to grow to about 325.3 M, whereas Tax Provision is projected to grow to (1.7 M).
2021 | 2022 | 2023 | 2024 (projected) | Reconciled Depreciation | 13.2M | 18.2M | 26.0M | 16.3M | Interest Income | 1.9M | 11.1M | 26.7M | 28.0M |
Ultragenyx fundamental ratios Correlations
Click cells to compare fundamentals
Ultragenyx Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Ultragenyx fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 1.1B | 1.8B | 1.5B | 1.5B | 1.5B | 856.5M | |
Other Current Liab | 83.2M | 140.9M | 134.5M | 192.9M | 225.7M | 237.0M | |
Total Current Liabilities | 103.3M | 189.6M | 181.4M | 261.2M | 280.4M | 294.5M | |
Total Stockholder Equity | 653.8M | 1.2B | 922.6M | 352.5M | 275.4M | 481.1M | |
Other Liab | 348.7M | 376.3M | 387.6M | 911.9M | 1.0B | 1.1B | |
Property Plant And Equipment Net | 74.7M | 114.0M | 176.2M | 285.7M | 290.6M | 305.1M | |
Net Debt | (396.6M) | (665.3M) | (265.6M) | (101.4M) | (170.4M) | (178.9M) | |
Retained Earnings | (1.4B) | (1.6B) | (2.1B) | (2.8B) | (3.4B) | (3.2B) | |
Accounts Payable | 12.9M | 12.9M | 17.1M | 43.3M | 42.1M | 44.2M | |
Cash | 433.6M | 713.5M | 307.6M | 132.9M | 213.6M | 202.9M | |
Non Current Assets Total | 284.5M | 464.3M | 665.8M | 661.5M | 758.8M | 796.8M | |
Non Currrent Assets Other | (4.2M) | (24.5M) | 11.6M | 10.7M | 57.7M | 60.6M | |
Other Assets | 3.5M | 8.8M | 20.6M | 16.8M | 19.4M | 20.3M | |
Cash And Short Term Investments | 760.4M | 1.2B | 999.1M | 896.7M | 577.2M | 543.4M | |
Net Receivables | 32.8M | 23.1M | 28.4M | 40.4M | 73.4M | 77.1M | |
Common Stock Total Equity | 58K | 67K | 69K | 70K | 80.5K | 44.1K | |
Common Stock Shares Outstanding | 56.6M | 60.8M | 67.8M | 69.9M | 73.5M | 50.9M | |
Liabilities And Stockholders Equity | 1.1B | 1.8B | 1.5B | 1.5B | 1.5B | 856.5M | |
Non Current Liabilities Total | 378.4M | 415.6M | 418.5M | 931.7M | 935.2M | 981.9M | |
Other Current Assets | 46.2M | 57.6M | 71.7M | 68.9M | 47.6M | 34.5M | |
Other Stockholder Equity | 2.1B | 2.8B | 3.0B | 3.1B | 3.7B | 3.8B | |
Total Liab | 481.7M | 605.2M | 599.8M | 1.2B | 1.2B | 1.3B | |
Property Plant And Equipment Gross | 74.7M | 114.0M | 226.2M | 349.1M | 374.0M | 392.7M | |
Total Current Assets | 851.0M | 1.3B | 856.6M | 883.9M | 732.2M | 564.7M | |
Accumulated Other Comprehensive Income | (147K) | 689K | (1.4M) | (6.6M) | 647K | 679.4K | |
Common Stock | 58K | 67K | 69K | 70K | 82K | 47.6K | |
Property Plant Equipment | 74.7M | 73.5M | 141.2M | 259.7M | 298.7M | 313.6M | |
Short Term Investments | 321.6M | 488.0M | 432.6M | 614.8M | 363.6M | 347.3M | |
Net Tangible Assets | 480.4M | 978.9M | 758.4M | 148.0M | 170.2M | 161.7M | |
Retained Earnings Total Equity | (1.4B) | (1.6B) | (2.1B) | (2.8B) | (2.5B) | (2.4B) | |
Capital Surpluse | 2.1B | 2.8B | 3.0B | 3.1B | 3.6B | 2.0B | |
Inventory | 11.5M | 13.0M | 16.2M | 26.8M | 34.0M | 35.7M | |
Non Current Liabilities Other | 345.1M | 382.3M | 385.2M | 4.8M | 12.2M | 11.6M | |
Intangible Assets | 129M | 131.1M | 130.8M | 160.1M | 166.3M | 108.7M | |
Long Term Investments | 32.9M | 10.5M | 258.9M | 154.5M | 199.9M | 108.0M | |
Net Invested Capital | 653.8M | 1.2B | 922.6M | 352.5M | 275.4M | 497.3M | |
Net Working Capital | 747.7M | 1.1B | 675.2M | 622.7M | 451.7M | 667.7M | |
Capital Stock | 58K | 67K | 69K | 70K | 82K | 72.8K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Ultragenyx is a strong investment it is important to analyze Ultragenyx's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ultragenyx's future performance. For an informed investment choice regarding Ultragenyx Stock, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Ultragenyx. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Ultragenyx Stock refer to our How to Trade Ultragenyx Stock guide.You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ultragenyx. If investors know Ultragenyx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ultragenyx listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.35) | Revenue Per Share 6.015 | Quarterly Revenue Growth 0.423 | Return On Assets (0.24) | Return On Equity (2.90) |
The market value of Ultragenyx is measured differently than its book value, which is the value of Ultragenyx that is recorded on the company's balance sheet. Investors also form their own opinion of Ultragenyx's value that differs from its market value or its book value, called intrinsic value, which is Ultragenyx's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ultragenyx's market value can be influenced by many factors that don't directly affect Ultragenyx's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ultragenyx's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ultragenyx is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ultragenyx's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.